Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VB 601

Next Previous
Drug Profile

VB 601

Alternative Names: VB-601

Latest Information Update: 07 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator VBL Therapeutics
  • Developer Notable Labs
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Cell proliferation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammation

Most Recent Events

  • 06 Sep 2023 VB 601 is still in preclinical trials for Inflammation in Israel
  • 28 Jul 2023 No recent reports of development identified for preclinical development in Inflammation in Israel (Parenteral)
  • 14 Mar 2023 VBL therapeutics plans a first-in-human phase-I clinical trial for chronic Inflammation (Parenteral) in the Q1 of 2023 (VBL Therapeutics pipeline; March 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top